University of Rhode Island College of Pharmacy, 7 Greenhouse Rd, Kingston, RI, 02881, USA.
Mass General North Shore Cancer Center, Danvers, MA, USA.
Curr Treat Options Oncol. 2021 Jan 12;22(2):14. doi: 10.1007/s11864-020-00807-y.
Mesothelioma is a rare and severe form of cancer that is associated with asbestos exposure. Approximately 2500 Americans die annually from this condition with a median survival of 1 year. The latency period of this disease ranges anywhere from 20 to 70 years, with shorter latency periods associated with a higher exposure intensity to asbestos. Therefore, cases of mesothelioma are expected in the coming decades. This highlights the need for clinicians to understand the pharmacologic regimens available for treating this rare, yet serious malignancy. With multiple treatment regimens available in the treatment of this condition, clinicians should take an evidence-based approach and consider the totality of evidence and safety information while considering the best patient-centered approach for treatment. This article provides a review of current pharmacologic treatment options available for mesothelioma and goes into detail about the recommended medication regimens and dosages and the available evidence of efficacy, effectiveness, and/or safety and estimates the annual cost of treatment for these medications on the U.S. healthcare system per patient. A brief introduction is provided for several promising agents currently under investigation for mesothelioma as well.
间皮瘤是一种罕见且严重的癌症，与石棉暴露有关。每年约有 2500 名美国人死于这种疾病，中位生存期为 1 年。这种疾病的潜伏期 anywhere from 20 到 70 年不等，潜伏期越短，接触石棉的强度越高。因此，预计在未来几十年会出现间皮瘤病例。这凸显了临床医生了解治疗这种罕见但严重恶性肿瘤的可用药物方案的必要性。由于有多种治疗方案可用于治疗这种疾病，临床医生应采用循证方法，并在考虑最佳以患者为中心的治疗方法时，考虑到所有证据和安全性信息。本文回顾了目前可用于间皮瘤的药物治疗选择，并详细介绍了推荐的药物方案和剂量，以及疗效、有效性和/或安全性的现有证据，并估计了这些药物在美国医疗保健系统中每位患者的治疗年度费用。本文还简要介绍了目前正在研究的几种有前途的间皮瘤治疗药物。
